H3B 6545

Drug Profile

H3B 6545

Alternative Names: H3B6545

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator H3 Biomedicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Estrogen-receptor-alpha-antagonist
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer

Most Recent Events

  • 18 Aug 2017 Phase-I/II clinical trials in Breast cancer (Metastatic disease) in USA (PO) (NCT03250676)
  • 02 Apr 2017 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top